GleamWall
中文EN

ZEOX Zeo ScientifiX, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1557376 · Fiscal year ends 06/30

Financial factors as of 2025-10-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY12.5%
TTM net income YoY-17.3%
TTM EPS YoY-16.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin82.1%
Operating margin-103.6%
Net margin-106.2%
FCF margin-14.3%
EBITDA margin-102.2%

Returns

ROE—
ROA-348.3%
ROIC (approx.)—
Asset turnover3.28x

Leverage & solvency

Liabilities / assets193.2%
Debt / equity—
Current ratio0.33x
Interest coverage-54.96x

Cash quality & payout

Operating cash flow / net income0.13x
Accruals ratio-303.0%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q22026-04-302026Q12026-01-312024Q4*2025-10-312025Q42025-09-302025Q32025-07-312025Q22025-04-302025Q12025-01-31
Income statement
Revenue$2.06M$2.58M$1.45M$1.65M$1.39M$1.31M$1.15M$1.09M
Cost of revenue$514,000$526,000$281,000$256,000$284,000$228,000$256,000$191,000
Gross profit$1.55M$2.06M$1.17M$1.40M$1.10M$1.08M$893,000$899,000
R&D expense$16$31,000$19,000—$20—$42,000$6,000
SG&A expense$3.81M$2.57M$2.04M$2.07M$2.03M$3.15M$2.29M$2.15M
Operating income-$2.26M-$512,000-$878,000-$668,000-$926,000-$2.07M-$1.39M-$1.25M
Interest expense$9,000$11,000$10,000$32,000$22,000$23,000$21,000$22,000
Net income-$2.21M-$145,000-$852,000-$815,000-$963,000-$2.07M-$1.39M-$1.24M
EBITDA-$2.24M-$493,000-$859,000-$648,000-$906,000-$2.05M-$1.38M-$1.24M
EPS (basic)-0.28-0.02-0.12—-0.15-0.32-0.22-0.20
EPS (diluted)-0.28-0.02-0.12—-0.15-0.32-0.22-0.20
Weighted avg. shares (diluted)7.84M7.76M7.02M—6.47M6.41M6.34M6.34M
Balance sheet
Cash & equivalents$1.24M$1.85M$1.03M$221,000$261,000$314,000$542,000$720,000
Receivables$331,000$276,000$63,000$35,000——$11,000$6,000
Inventory$934,000$686,000$502,000$423,000—$258,000$235,000$245,000
Current assets$2.79M$3.27M$2.01M$958,000—$1.06M$865,000$1.09M
PP&E, net$574,000$609,000$564,000$569,000—$589,000$570,000$460,000
Total assets$3.42M$3.89M$2.57M$1.53M—$1.65M$1.44M$1.55M
Current liabilities$4.52M$3.11M$2.89M$2.87M—$3.88M$3.45M$3.35M
Short-term debt—$247,000$245,000$243,000—$698,000$692,000$686,000
Total liabilities$4.58M$3.17M$2.95M$2.95M—$3.97M$3.54M$3.35M
Shareholders' equity-$1.14M$712,000-$383,000-$1.42M-$2.20M-$2.31M-$2.10M-$1.80M
Shares outstanding7.84M7.79M7.61M6.75M—6.50M6.34M6.34M
Cash flow statement
Operating cash flow-$768,000-$138,000-$471,000-$383,000-$128,000-$257,000-$143,000$65,000
Capital expenditure—$64,000$14,000$0————
Free cash flow—-$202,000-$485,000-$383,000————
Investing cash flow—$312,000-$14,000$0————
Financing cash flow-$257,000$642,000$1.29M$290,000$247,000$52,000-$35,000-$2,000
Depreciation & amortization$21,000$19,000$19,000$20,000$20,000$19,000$16,000$18,000
Stock-based compensation$478,000$590,000$592,000$756,000$852,000$1.75M$1.10M$1.09M

Free plan shows the latest 8 periods; Pro shows all 60 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.